Last Updated: November 16, 2026

Patent: 8,562,978

« Back to Dashboard


Summary for Patent: 8,562,978
Title:Stable digestive enzyme compositions
Abstract: Compositions of the present invention, comprising at least one digestive enzyme (e.g., pancrelipase) are useful for treating or preventing disorders associated with digestive enzyme deficiencies. The compositions of the present invention can comprise a plurality of coated particles, each of which is comprised of a core coated with an enteric coating comprising at least one enteric polymer and 4-10% of at least one alkalinizing agent, or have moisture contents of about 3% or less, water activities of about 0.6 or less, or exhibit a loss of activity of no more than about 15% after six months of accelerated stability testing.
Inventor(s): Ortenzi; Giovanni (Monza, IT), Marconi; Marco (Cinisello Balsamo, IT), Mapelli; Luigi (Milan, IT)
Assignee: Aptalis Pharma Limited (Wicklow, IE)
Application Number:12/832,596
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

US Patent 8,562,978: What Do the Claims Actually Cover, and How Crowded Is the Landscape?

US Patent 8,562,978 claims a pancrelipase powder made of plurality of coated particles, where each particle is a core containing pancrelipase plus disintegrant/binder (and optionally conventional excipients), followed by an enteric coating that includes an enteric polymer and 4 to 10 wt% of an alkalinizing agent. The patent further narrows to low moisture / low water activity and specific material pairings (notably croscarmellose sodium + microcrystalline cellulose, coated with HPMCP and talc; plasticizers include HCO and triethyl citrate).

The claims also extend to filled capsules containing the coated particles, with explicit moisture caps and a capsule shell defined by HPMC for two dependents.


What Is Claimed, in Claim-Scope Terms?

1) Core composition structure

Independent claim 1 requires a particle having:

  • Core comprising:
    • pancrelipase
    • at least one disintegrant
    • at least one polymeric binder
  • Enteric coating comprising:
    • at least one enteric polymer
    • 4–10 wt% alkalinizing agent (based on total composition weight)

This is a composition-and-process-of-composition claim that is limited by both:

  • formulation architecture (core + enteric coating), and
  • a quantitative alkalinizer band inside the enteric coating system.

2) Moisture and water-activity limits

Claims 2–4 add performance spec limits that constrain the formulation state:

  • Moisture ≤ ~3% (claim 2)
  • Moisture ≤ ~2% (claim 3)
  • Water activity ≤ 0.6 (claim 4)

These are not “standard packaging” claims. They force a manufacturing and storage-relevant property to be within a narrow envelope, which can matter for enforceability because infringement can hinge on measured values.

3) Locked-down excipient identity (core and coating)

Claim 5 specifies the exact exemplified set:

  • Disintegrant: croscarmellose sodium
  • Binder: microcrystalline cellulose
  • Enteric polymer: hydroxypropylmethylcellulose phthalate (HPMCP)
  • Alkalinizing agent: talc

Claims 6–7 expand the “optional” excipient universe into defined embodiments:

  • Core excipients (claim 6): optional plasticizers, glidants, lubricants
  • Coating plasticizer (claim 6): at least one plasticizer
  • Claim 7 fixes:
    • Core: hydrogenated castor oil, colloidal silicon dioxide, magnesium stearate
    • Coating plasticizer: triethyl citrate

4) Quantitative banding of pancrelipase and excipient loading

Claims 8 and 10 lock more numbers:

  • Claim 8 core banding:
    • pancrelipase 60–90 wt%
    • disintegrant 1–4 wt%
    • polymeric binder 2–6 wt%
  • Claim 10 enteric coating:
    • HPMCP 10–20 wt%

Claim 11 is the most detailed “bill of materials”:

Core (total composition basis):

  • pancrelipase 60–90%
  • disintegrant 1–4%
  • plasticizer 0.5–1.0%
  • glidant 0.2–0.6%
  • binder 2–6%
  • lubricant 0.2–0.6%

Coating:

  • enteric polymer 10–20%
  • alkalinizing agent 4–10%
  • plasticizer 1–2%

Claim 12 pins down the identities:

  • disintegrant: croscarmellose sodium
  • core plasticizer: hydrogenated castor oil
  • binder: microcrystalline cellulose
  • lubricant: magnesium stearate
  • enteric polymer: HPMCP
  • alkalinizer: talc
  • coating plasticizer: triethyl citrate

5) Capsule shell and moisture caps

Claims 13–16 add moisture limits on the capsule-containing product:

  • Capsule filled with claim 1 particles:
    • moisture < ~4% (claim 13)
    • moisture < ~2% (claim 14)
  • Capsule filled with claim 11 particles:
    • moisture < ~4% (claim 15)
    • moisture < ~2% (claim 16)

Claims 17–18 define a capsule made from:

  • hydroxypropylmethylcellulose (HPMC) filled with particles of claim 1 (17) or claim 11 (18)

What Is the “Key Patentable Concept” in These Claims?

The claims repeatedly converge on one central differentiator: enteric coating composition includes an alkalinizing agent at 4–10 wt% paired with a specific enteric polymer system (HPMCP) and a stable low-water formulation state.

From a patent landscape standpoint, this means the enforceable feature is not just “enteric coated pancrelipase,” which is well-established. It is the combination of:

  1. Core with pancrelipase + disintegrant + binder, and
  2. enteric coating includes alkalinizer at a specific loading band (4–10 wt%), and
  3. low moisture / low water activity constraints (claims 2–4 and capsule moisture claims 13–16), and
  4. exemplified excipient identities (claims 5 and 12) that reduce interpretation latitude.

How Does This Fit the Known Pancrelipase / Enteric-Coated Enzyme Formulation Reality?

A crowded baseline

The general approach of delivering pancrelipase with enteric protection is a standard industry solution to protect enzymes from gastric acid. As a result, the landscape typically contains many claims around:

  • enteric polymer selection (HPMCP vs methacrylic copolymers),
  • coating weight gain / thickness,
  • plasticizer selection,
  • granulation and drying methods,
  • moisture control approaches.

Where this patent likely draws the line

This patent draws a line through two quantifications that are easier to defend than “generic enteric coating”:

  • Alkalinizing agent loading band: 4–10 wt%
  • Water activity and moisture ceilings: moisture ≤ 2–3%, aw ≤ 0.6, and capsule-specific moisture caps ≤ 2–4%

Implication

In claim construction and enforcement, these elements push the analysis toward:

  • the accused product’s coating formula math (what the alkalinizer is and its loading), and
  • measured physical-state metrics (moisture and water activity), not just coating presence.

Claim-by-Claim Criticality: Which Elements Most Affect Infringement Risk?

Independent claim 1: the main battleground

Claim 1 is broad on excipient identity while narrow on architecture and alkalinizer band:

  • “plurality of coated particles”
  • “core coated with an enteric coating”
  • core includes pancrelipase + disintegrant + polymeric binder
  • enteric coating includes enteric polymer + alkalinizing agent at 4–10 wt%

Most infringement-sensitive features:

  • presence of a plurality of coated particles (not a bulk blend in one matrix),
  • a coated core structure,
  • an alkalinizing agent inside the enteric coating at 4–10 wt%.

Dependent claim 2–4: physical state constraints

Moisture and aw limits are highly measurable. They can become a defense if the accused product is manufactured/stored outside these ranges.

  • Claim 2 (≤3%) and claim 3 (≤2%) tighten further.
  • Claim 4 (aw ≤0.6) is often not routinely published by developers and may require testing under defined conditions.

Dependent claim 5 and 12: literal material identity locks

Where companies substitute materials:

  • talc vs other alkalinizers,
  • HPMCP vs other enteric polymers,
  • microcrystalline cellulose vs other binders,
  • croscarmellose sodium vs other disintegrants,

they may avoid literal infringement of these dependents while still risking claim 1 coverage.

Dependent claim 11: detailed “formulation bill”

Claim 11 is a claim-stacking trap:

  • it specifies every major core component and each has narrow bands,
  • and it specifies coating bands including alkalinizer.

A product that drifts outside any one band reduces literal infringement.

Capsule claims (13–18)

If the product is marketed as capsule-filled pancrelipase particles, these claims can matter. But if a product uses different capsule shell material, claims 17–18 can be avoided, while claims 13–16 may still attach if moisture limits are met.


Patent Landscape: Likely Claim Cluster and How 8,562,978 Sits

Likely cluster around “enteric-coated pancrelipase granules”

Most relevant prior art and competitor patents in this area typically cover:

  • enteric coating polymers for enzyme pellets/granules,
  • coating plasticizers and glidants,
  • methods to produce low-moisture enzyme powders,
  • use of alkalinizing agents with enteric polymers (sometimes tied to protective performance against gastric acid).

This patent’s differentiator relative to typical clusters

8,562,978 stands out for tying:

  • alkalinizing agent loading band directly into the enteric coating definition (4–10 wt%),
  • and coupling it to low moisture and water activity limits.

That structure is designed to narrow around a specific formulation strategy rather than just polymer chemistry or general low-moisture processing.


Enforceability Drivers: What Claim Language Will Matter in Litigation

1) “Based on total weight of the composition”

The alkalinizing agent definition is tied to “based on total weight of the composition.” That limits ambiguity about whether the loading is relative to the coating fraction or the entire formulation. This tends to improve enforceability if measurement uses a consistent basis.

2) Moisture and water activity

If the accused product is:

  • a different packaging/storage regime,
  • a different target moisture,
  • or manufactured to different aw thresholds,

then dependent claim infringement becomes fact-intensive and test-dependent.

3) Architecture requirement

“Plurality of coated particles” plus “each comprised of a core coated with an enteric coating” matters. Products that:

  • use different physical forms,
  • or incorporate enteric polymer in a matrix without discrete coated cores, may attempt to distinguish on structure.

Freedom-to-Operate (FTO) Implications for Developers and Generic Entrants

Based on the claim scope, an FTO position typically hinges on three technical questions:

  1. Is the product built as coated particles with coated cores?
  2. Does the enteric coating contain an alkalinizing agent at 4–10 wt% (total composition basis)?
  3. Are moisture and/or water activity within the dependent ranges?

A product could potentially evade:

  • dependent claims by selecting different excipient identities, while still risking independent claim 1 if the architecture and alkalinizer band match.

Key Takeaways

  • US 8,562,978 is anchored on enteric-coated pancrelipase particles with an alkalinizing agent in the enteric coating at 4–10 wt% and optional but narrowing constraints on moisture (≤3% or ≤2%) and water activity (≤0.6).
  • The most enforceable lever is the 4–10 wt% alkalinizer band tied to the enteric coating, reinforced by explicit physical-state limits in dependent claims.
  • The most easily designed-around elements are the material identity dependents (e.g., talc, HPMCP, croscarmellose sodium, microcrystalline cellulose) and the fine-grained bill-of-materials bands in claim 11.
  • Capsule claims add an additional infringement axis if the market product is a capsule-filled formulator with moisture within the claimed limits; shell material matters only for HPMC capsule dependents (17–18).

FAQs

1) What is the central claim limitation that likely differentiates this patent from generic enteric-coated pancrelipase?

The enteric coating includes an alkalinizing agent at 4–10 wt% (based on total weight of the composition), paired with a core containing pancrelipase plus disintegrant and polymeric binder.

2) Are moisture and water activity requirements only in dependent claims?

Yes. Moisture ≤3%, moisture ≤2%, and water activity ≤0.6 appear in dependent claims 2–4, while capsule moisture limits appear in 13–16.

3) If a competitor uses a different alkalinizer than talc, does it avoid claim 5 or 12?

Yes for the dependents that lock the identity to talc (claim 5 and the specific version in claim 12), but claim 1 can still be implicated if the alkalinizer is within 4–10 wt% and other structural requirements match.

4) Does claim coverage require specific percentages of pancrelipase for infringement of claim 1?

No. The 60–90 wt% pancrelipase band appears in dependent claims 8 and 11. Claim 1 requires pancrelipase to be present in the core but does not fix a pancrelipase percentage.

5) Do the capsule claims require an HPMC capsule shell?

No. Claims 13–16 focus on capsule-filled products and moisture limits, while claims 17–18 add the capsule shell requirement that the capsule is hydroxypropylmethylcellulose.


References

  1. US Patent 8,562,978.

More… ↓

⤷  Start Trial

Details for Patent 8,562,978

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Organon Usa Inc., A Subsidiary Of Merck & Co., Inc. COTAZYM pancrelipase Capsule, Delayed Release 020580 December 9, 1996 ⤷  Start Trial 2030-07-08
Abbvie Inc. CREON pancrelipase Capsule, Delayed Release 020725 April 30, 2009 ⤷  Start Trial 2030-07-08
Abbvie Inc. CREON pancrelipase Capsule, Delayed Release 020725 June 10, 2011 ⤷  Start Trial 2030-07-08
Abbvie Inc. CREON pancrelipase Capsule, Delayed Release 020725 March 14, 2013 ⤷  Start Trial 2030-07-08
Digestive Care, Inc. PERTZYE pancrelipase Capsule, Delayed Release 022175 May 17, 2012 ⤷  Start Trial 2030-07-08
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.